+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy



Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy



Clinical Infectious Diseases 40(3): 468-474



The prevalence of drug resistance among persons with newly acquired human immunodeficiency virus (HIV) infection is well documented. However, it is unclear to what extent these mutations persist in chronically infected, treatment-naive patients. Prevalence of and factors associated with genotypic drug resistance were analyzed retrospectively in a subset of 491 chronically HIV-infected, antiretroviral-naive patients enrolled at 25 cities in the Terry Beirn Community Programs for Clinical Research on Acquired Immune Deficiency Syndrome (AIDS) Flexible Initial Retrovirus Suppressive Therapies trial during 1999-2001. Resistance was defined on the basis of the International AIDS Society 2003 definition, as well as the presence of additional mutations at codons 215 (C/D/E/S) and 69 (A/N/S) in the pol gene. Prevalence of mutations was estimated by use of techniques for stratified random samples. Logistic regression models were used to determine factors associated with resistance. Among the 491 chronically HIV-infected patients (mean CD4 cell count, 269 cells/mm(3); 31% of patients had a prior AIDS diagnosis), 57 (11.6%) had >or=1 resistance mutation, resulting in an estimated prevalence for the cohort of 10.8% (95% confidence interval [CI], 9.5%-12.1%). The prevalence was 8.8% if the 118I mutation was excluded. By drug class, the estimated prevalence of mutations conferring resistance to nucleoside reverse-transcriptase inhibitors was 7.8%, and the prevalence was 3.0% for nonnucleoside reverse-transcriptase inhibitors and 0.7% for protease inhibitors. In a multiple logistic regression analysis, non-Hispanic white subjects were twice as likely than African American subjects to have resistance (odds ratio [OR], 2.1; 95% CI, 1.1-4.1; P=.03), and there was a 40% increase per year in prevalence of mutations by later year of enrollment (OR, 1.4; 95% CI, 1.0-2.1; P=.05). These results demonstrate the persistence of drug resistance mutations in chronically HIV-infected patients and an increasing prevalence of resistance over time, and they support genotyping of virus at baseline for chronically HIV-infected patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012446432

Download citation: RISBibTeXText

PMID: 15668873

DOI: 10.1086/427212


Related references

Research of antiretroviral drug resistance in antiretroviral-naive patients and in antiretroviral-experienced chronically infected patients in Beijing and the impact of the resistance to treatment. Zhonghua Weishengwuxue He Mianyixue Zazhi 27(11): 1011-1015, 2007

Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clinical Trials 8(1): 1-8, 2007

Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. Journal of the International Aids Society 15(1): 12-12, 2012

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. Journal of Antimicrobial ChemoTherapy 2019, 2019

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. Journal of Antimicrobial ChemoTherapy 65(12): 2620-2627, 2011

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States. Aids Research and Human Retroviruses 34(8): 672-679, 2018

Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study. Aids 15(14): 1777-1782, 2001

French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. Journal of Acquired Immune Deficiency Syndromes 38(5): 545-552, 2005

Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China. Zhonghua Shi Yan He Lin Chuang Bing du Xue Za Zhi 18(4): 308-311, 2005

Virologic response to antiretroviral therapy in chronically HIV-1-infected, antiretroviral-naive adults with baseline genotypic resistance. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 333, 2001

Antiretroviral drug resistance among antiretroviral-naïve and treatment experienced patients infected with HIV in Iran. Journal of Medical Virology 86(7): 1093-1098, 2015

Prevalence of antiretroviral drug resistance among treatment-naive and treated HIV-infected patients in Venezuela. Memorias do Instituto Oswaldo Cruz 104(3): 522-525, 2009

Prevalence of antiretroviral drug resistance among treatment-naive and treated Hiv-infected patients in Venezuela. Memórias do Instituto Oswaldo Cruz 104(3): 522-525, 2009

Mutations associated with genotypic resistance to antiretroviral therapy in treatment naive HIV-1 infected patients in Greece. Virus Research 85(1): 109-115, 23 April, 2002

HIV-1 subtypes and primary antiretroviral resistance mutations in antiretroviral therapy naive HIV-1 infected individuals in Turkey. Japanese Journal of Infectious Diseases 66(4): 306-311, 2014